Dr. Albiges on Next Steps for Immunotherapy in RCC

Video

Laurence Albiges, MD, ‎medical oncologist, head, Genitourinary Oncology Unit, Gustave Roussy, discusses the next steps for immunotherapy for patients with renal cell carcinoma (RCC).

Laurence Albiges, MD, ‎medical oncologist, head, Genitourinary Oncology Unit, Gustave Roussy, discusses the next steps for immunotherapy for patients with renal cell carcinoma (RCC).

There is now access to nivolumab (Opdivo) in most countries due to its efficacy in overall survival compared with everolimus (Afinitor) and its safety profile, explains Albiges.

However, given the risks that still exist, more needs to be done to continue to develop the treatment landscape, states Albiges. Physicians are now investigating combination strategies that might improve outcomes.

Related Videos
Shivaani Kummar, MBBS, FACP, Margaret and Lester DeArmond Endowed Chair of Cancer Research, Professor and Division Head, Division of Hematology/Medical Oncology, Oregon Health & Science University School of Medicine; co-director, Center for Experimental Therapeutics, co-deputy director, Knight Cancer Institute
Andre Goy, MD
Wenxin (Vincent) Xu, MD,
Guenther Koehne, MD, PhD
Alessandro Villa, DDS, PhD, MPH
Joseph Mikhael, MD
Michael Richardson, MD
Minesh Mehta, MD
Ruben Olivares, MD
Phillip J. Koo, MD